UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,628 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 5.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 78,807 shares of the company's stock after selling 4,628 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.25% of Medpace worth $26,182,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in MEDP. Invesco Ltd. increased its holdings in shares of Medpace by 91.8% in the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after purchasing an additional 519,186 shares during the last quarter. Proficio Capital Partners LLC grew its stake in shares of Medpace by 34,497.4% in the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after acquiring an additional 241,827 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Medpace in the fourth quarter valued at about $78,144,000. Norges Bank acquired a new position in shares of Medpace in the fourth quarter valued at about $69,859,000. Finally, GW&K Investment Management LLC grew its stake in shares of Medpace by 93.9% in the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after acquiring an additional 133,379 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Insider Transactions at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director now owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 20.30% of the stock is owned by insiders.

Medpace Stock Down 0.2%

MEDP traded down $0.60 during trading hours on Friday, hitting $296.45. The stock had a trading volume of 315,099 shares, compared to its average volume of 353,822. The company's fifty day simple moving average is $299.48 and its 200 day simple moving average is $325.24. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The stock has a market cap of $8.52 billion, a PE ratio of 23.47, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. The company had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter last year, the firm posted $3.20 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Robert W. Baird reduced their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Mizuho reduced their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Finally, Leerink Partners initiated coverage on shares of Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective on the stock. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Medpace presently has an average rating of "Hold" and an average price target of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.